Two-year pemafibrate treatment reduced median liver stiffness by 0.54 kPa from 3.05 to 2.52 kPa in MASLD patients with hypertriglyceridemia, indicating fibrosis improvement (P < 0.001).
Observational (n=25)
No
Does pemafibrate improve liver fibrosis in patients with MASLD and hypertriglyceridemia?
Pemafibrate demonstrates potential hepatoprotective and antifibrotic effects in patients with MASLD and hypertriglyceridemia, independent of weight loss.
Estimación del efecto: -0.54 kPa (Hodges–Lehmann estimate) (95% CI -0.86 to -0.31 kPa)
Tasa de eventos absoluta: 2.52% vs 3.05%
valor p: p=<0.001
Two-year pemafibrate treatment significantly improved liver stiffness and hepatic parameters independent of weight loss or fat reduction, indicating potential antifibrotic mechanisms. These real-world findings support the hepatoprotective role of pemafibrate and warrant validation in prospective trials.
Noritake et al. (Sun,) conducted a observational in Metabolic dysfunction–associated steatotic liver disease (MASLD) and hypertriglyceridemia (n=25). Pemafibrate vs. None (single-arm observational study) was evaluated on Change in magnetic resonance elastography-derived liver stiffness measurement (MRE-LSM) at 2 years (-0.54 kPa (Hodges–Lehmann estimate), 95% CI -0.86 to -0.31 kPa, p=<0.001). Two-year pemafibrate treatment reduced median liver stiffness by 0.54 kPa from 3.05 to 2.52 kPa in MASLD patients with hypertriglyceridemia, indicating fibrosis improvement (P < 0.001).